Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Asia Development Capital / Equity Bottom-Up

<ul>
 <li>
DELISTED ENTITY WITH SEVERE GOVERNANCE ISSUES: <a href="https://smartkarma.com/entities/asia-development-capital-co-ltd">Asia Development Capital</a> (ADC) was delisted from the Tokyo Stock Exchange on April 30, 2023, due to its failure to improve its internal management systems following revelations of inappropriate accounting. This event is central to any assessment of the company and renders it an extremely high-risk entity, unsuitable for typical institutional investment.</li>
 <li>
POST-DELISTING RESTRUCTURING AND UNCERTAIN STRATEGY: Following the delisting, ADC has undergone a management overhaul, with a new CEO appointed in May 2023. The company's website indicates a continued focus on investment activities in Japan and Asia, but the viability and transparency of its operations as a private entity are highly uncertain. The company's future is contingent on its ability to rebuild trust and operate without access to public capital markets.</li>
 <li>
HISTORICAL FOCUS ON JAPAN-ASIA BRIDGE WITH FLAWED EXECUTION: Historically, ADC aimed to connect Japanese capital with growth opportunities in China and Southeast Asia, focusing on sectors like renewable energy and private welfare. However, its strategy was marred by significant governance failures, leading to its eventual delisting and casting serious doubt on its ability to execute its stated objectives.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
DELISTED ENTITY WITH SEVERE GOVERNANCE ISSUES: Asia Development Capital (ADC) was delisted from the Tokyo Stock Exchange on April 30, 2023, due to its failure to improve its internal management systems following revelations of inappropriate accounting. This event is central to any assessment of the company and renders it an extremely high-risk entity, unsuitable for typical institutional investment.
  
POST-DELISTING RESTRUCTURING AND UNCERTAIN STRATEGY: Following the delisting, ADC has undergone a management overhaul, with a new CEO appointed in May 2023. The company's website indicates a continued focus on investment activities in Japan and Asia, but the viability and transparency of its operations as a private entity are highly uncertain. The company's future is contingent on its ability to rebuild trust and operate without access to public capital markets.
  
HISTORICAL FOCUS ON JAPAN-ASIA BRIDGE WITH FLAWED EXECUTION: Historically, ADC aimed to connect Japanese capital with growth opportunities in China and Southeast Asia, focusing on sectors like renewable energy and private welfare. However, its strategy was marred by significant governance failures, leading to its eventual delisting and casting serious doubt on its ability to execute its stated objectives.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Asia Development Capital (9318 JP) - Aug 2026

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Thematic (Sector/Industry)

<ul>
<li>This is part of a series of M&amp;A guides that our Quiddity* <a href="https://www.smartkarma.com/companies/quiddity-advisors/team" target="_blank" rel="noopener">team</a> is publishing to aid investors in understanding the rules, parameters, possibilities, and processes in M&amp;A. </li>
<li>They are designed to contain links to all the relevant rules, oversight entities, and provide details as to how M&amp;A is conducted and what rules apply.</li>
<li>In many of the insights on deals in specific markets and countries, these insights will be used as points of reference. </li>
</ul>


This is part of a series of M&amp;A guides that our Quiddity* team is publishing to aid investors in understanding the rules, parameters, possibilities, and processes in M&amp;A. 
They are designed to contain links to all the relevant rules, oversight entities, and provide details as to how M&amp;A is conducted and what rules apply.
In many of the insights on deals in specific markets and countries, these insights will be used as points of reference. 


Event-Driven

<ul>
<li>On 24 May, <a href="https://www.smartkarma.com/entities/toyo-construction-co-ltd" target="_blank" data-smartkarma-citation="entities:1176:1" rel="noopener">Toyo Construction (1890 JP)</a> (TC) came out fighting against Yamauchi No.10 Family Office (YFO), presenting a poison pill and accusing YFO of "extreme dishonesty" despite standstill agreement. </li>
<li>YFO presented hundreds of pages of defence, TC continued to accuse the YFO co-CIO and others of wrongdoing. To me, TC was clearly acting in bad faith. </li>
<li>After ISS and later Glass Lewis came out against TC's proposal, YFO continued to ask for the PP to be pulled, TC has finally relented. Now we wait some more.</li>
</ul>


On 24 May, Toyo Construction (1890 JP) (TC) came out fighting against Yamauchi No.10 Family Office (YFO), presenting a poison pill and accusing YFO of "extreme dishonesty" despite standstill agreement. 
YFO presented hundreds of pages of defence, TC continued to accuse the YFO co-CIO and others of wrongdoing. To me, TC was clearly acting in bad faith. 
After ISS and later Glass Lewis came out against TC's proposal, YFO continued to ask for the PP to be pulled, TC has finally relented. Now we wait some more.


Toyo Cancels Poison Pill At Last Minute - Range to the Upside

<ul>
<li>On 17 November, <a href="https://www.smartkarma.com/entities/tokyo-kikai-seisakusho-ltd" target="_blank" data-smartkarma-citation="entities:15295:1" rel="noopener">Tokyo Kikai Seisakusho (6335 JP)</a> announced an agreement with ADC to hold off on issuing the rights against an ADC pledge to not call an EGM.</li>
<li>On 18 November, the Supreme Court handed down its rejection of the <a href="https://www.smartkarma.com/entities/asia-development-capital-co-ltd" target="_blank" data-smartkarma-citation="entities:5545:1" rel="noopener">Asia Development Capital (9318 JP)</a> appeals.</li>
<li>The immediate hostility is dialled back, the stalemate is extended. Every buyer from now on is a potential bagholder.</li>
</ul>


On 17 November, Tokyo Kikai Seisakusho (6335 JP) announced an agreement with ADC to hold off on issuing the rights against an ADC pledge to not call an EGM.
On 18 November, the Supreme Court handed down its rejection of the Asia Development Capital (9318 JP) appeals.
The immediate hostility is dialled back, the stalemate is extended. Every buyer from now on is a potential bagholder.


Tokyo Kikai Seisakusho (6335) Court Approved Poison Pill Stalemate Extended (Means Selling)

A bit over a week ago on 22 October, <a href="https://www.smartkarma.com/entities/tokyo-kikai-seisakusho-ltd" target="_blank" data-smartkarma-citation="entities:15295:1" rel="noopener">Tokyo Kikai Seisakusho (6335 JP)</a> held its EGM to have shareholders vote on its Poison Pill designed to limit the expansion of voting rights of its major shareholder <a href="https://www.smartkarma.com/entities/asia-development-capital-co-ltd" target="_blank" data-smartkarma-citation="entities:5545:1" rel="noopener">Asia Development Capital (9318 JP)</a> ("ADC") and its affiliated funds (but not specifically including any other shareholders who may or may not be acting in a highly correlated manner). The Shareholder Approval of the Poison Pill was discussed in <a href="https://www.smartkarma.com/insights/tokyo-kikai-seisakusho-6335-court-approves-poison-pill" target="_blank" data-smartkarma-citation="insights:59400" rel="noopener">Tokyo Kikai Seisakusho (6335) - Shareholders Approve Poison Pill</a>. The shareholder vote announcement at the time did not provide results, but later that night, ADC <a href="http://www.asiadevelop.com/wp-content/uploads/2021/10/a650bad5079f7074791163b02b4dedf5.pdf" target="_blank" rel="noopener">announced</a> that it objected to the fact that its votes had not been counted, and noted that had its votes been counted, it the combination of its votes and the other objectors would have defeated the Poison Pill. Because of the treatment of the major shareholder, it meant that this would definitely end up being decided by the Tokyo District Court last week, then likely appealed. But we knew that beforehand.That's where it went a little weird. While at first glance it appears as if the Tokyo District Court decision sets a terrible precedent (it does), one could imagine there may be legal ramifications if the Tokyo District Court decision is upheld in higher courts.

A bit over a week ago on 22 October, Tokyo Kikai Seisakusho (6335 JP) held its EGM to have shareholders vote on its Poison Pill designed to limit the expansion of voting rights of its major shareholder Asia Development Capital (9318 JP) ("ADC") and its affiliated funds (but not specifically including any other shareholders who may or may not be acting in a highly correlated manner). The Shareholder Approval of the Poison Pill was discussed in Tokyo Kikai Seisakusho (6335) - Shareholders Approve Poison Pill. The shareholder vote announcement at the time did not provide results, but later that night, ADC announced that it objected to the fact that its votes had not been counted, and noted that had its votes been counted, it the combination of its votes and the other objectors would have defeated the Poison Pill. Because of the treatment of the major shareholder, it meant that this would definitely end up being decided by the Tokyo District Court last week, then likely appealed. But we knew that beforehand.That's where it went a little weird. While at first glance it appears as if the Tokyo District Court decision sets a terrible precedent (it does), one could imagine there may be legal ramifications if the Tokyo District Court decision is upheld in higher courts.

Tokyo Kikai Seisakusho (6335) - Poison Pill Approval Appealed and Possible Silver Linings

Japan

Asia Development Capital Co., Ltd. is an investment holdings company and makes investments in Japan and China. The Company links business partners in both countries to form joint businesses for the development of Japan and China. Their focused area of investments includes private welfare in aging society, urban problem, and recyclable energy.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Asia Development Capital (9318 JP)

Primer: Asia Development Capital (9318 JP) - Aug 2026

DELISTED ENTITY WITH SEVERE GOVERNANCE ISSUES: Asia Development Capital (ADC) was delisted from the Tokyo Stock Exchange on April 30, 2023, due...

αSK Primers

Quiddity Japan M&A Guide 2022

The 2022 version of the Quiddity Japan M&A Guide with the rules and regulations and practices surrounding Mergers and Acquisitions in Japan as they...

Travis Lundy

Toyo Cancels Poison Pill At Last Minute - Range to the Upside

Toyo Construction - after weeks of accusations/defamation against YFO - has decided to withdraw its poison pill. That is positive, and suggests...

Travis Lundy

Tokyo Kikai Seisakusho (6335) Court Approved Poison Pill Stalemate Extended (Means Selling)

TKS extended the stalemate on condition ADC sell down. The Supreme Court dismissed ADC's objections. The Poison Pill is now suspended, not...

Travis Lundy

Tokyo Kikai Seisakusho (6335) - Poison Pill Approval Appealed and Possible Silver Linings

10 days ago, a majority of uninterested parties approved TKS' poison pill. The problem? "Interested Parties" is not a thing in the Companies Act....

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)